Opinion: miRNAs – The new wave of molecular cancer therapeutics

Hernando Lopez-Bertoni; John Laterra

Translational Oncology (Jun 2021)

Opinion: miRNAs – The new wave of molecular cancer therapeutics

Hernando Lopez-Bertoni,
John Laterra

Affiliations

Hernando Lopez-Bertoni: Hugo W. Moser Research Institute at Kennedy Krieger, 707N. Broadway, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA; Corresponding author at: Department of Neurology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA.
John Laterra: Hugo W. Moser Research Institute at Kennedy Krieger, 707N. Broadway, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA

Journal volume & issue: Vol. 14, no. 6
p. 101064

Abstract

Read online

Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation.

Published in Translational Oncology

ISSN: 1944-7124 (Print); 1936-5233 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/translational-oncology/

About the journal